Skip to main content
SpringerLink
Log in

PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications

  • Review Article
  • Published:
Clinical and Translational Imaging Aims and scope Submit manuscript

Abstract

The aim of this paper is to review the role of 18F-choline or 11C-cholinePET/CT in prostate cancer patients for diagnosis, staging and restaging in case of biochemical recurrence and on the use of 18F-choline or 11C-choline PET/CT for metastases directed salvage therapies and in castrate-resistant patients treated with systemic therapy. A literature search was performed, and articles related to 11C-choline and 18F-choline PET/CT in prostate cancer staging and biochemical relapse were identified. Search terms were: “PET” and “PET/CT”, “11C-choline”, “18F-choline”, “prostate cancer staging”, “lymph node staging” “biochemical recurrence”. We have reported the results of the most relevant publications following the criteria of clinical relevance, confirmations of choline PET/CT findings with histology, other imaging methods or clinical follow-up. Moreover, we have briefly reported about the use of 18F-choline or 11C-choline PET/CT for prostate cancer diagnosis and to monitor castrate-resistant prostate cancer (CRPC) patients treated with systemic therapy. In lymph node and distant staging choline, PET/CT showed low sensitivity but, in most of the cases, a relatively high specificity. In case of biochemical recurrence, PSA absolute value and PSA kinetics confirmed their strict correlation with choline PET/CT findings. Choline PET/CT resulted to be very useful to address salvages therapies, especially in the early phases of biochemical recurrence. The use of choline PET/CT in CRPC should be more deeply investigated. At the moment, its use in the diagnosis of prostate cancer is not recommended. 18F-choline or 11C-choline PET/CT provides useful information to clinicians mostly in case of biochemical recurrence, while the low sensitivity limits its use during staging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. ESMO Guidelines Task Force (2005) ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol 16(suppl 1):i34–i36

    Google Scholar 

  2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N (2014) EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 65(1):124–137

    Article  PubMed  Google Scholar 

  3. Farsad M, Schwarzenböck S, Krause BJ (2012) PET/CT and choline: diagnosis and staging. Q J Nucl Med Mol Imaging 56(4):343–353

    CAS  PubMed  Google Scholar 

  4. Schiavina R, Scattoni V, Castellucci P et al (2008) 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54:392–401

    Article  PubMed  Google Scholar 

  5. Contractor K, Challapalli A, Barwick T et al (2011) Use of [11C] choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res 17:7673–7683

    Article  CAS  PubMed  Google Scholar 

  6. Poulsen MH, Bouchelouche K, Hoilund-Carlsen PF et al (2012) [18F] fluoromethylcholine(FCH) positron emission tomography/computed tomography (PET/CT) for lymphnode staging of prostate cancer: a prospective study of 210 patients. BJU Int 110:1666–1671

    Article  CAS  PubMed  Google Scholar 

  7. Van den Bergh L, Lerut E, Haustermans K, Deroose CM, Oyen R, Isebaert S, Budiharto T, Ameye F, Mottaghy FM, Bogaerts K, Van Poppel H, Joniau S (2015) Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urol Oncol 33(3):109.e23–109.e31

    Article  Google Scholar 

  8. Evangelista L, Guttilla A, Zattoni F, Muzzio PC (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and metaanalysis. Eur Urol 63:1040–1048

    Article  PubMed  Google Scholar 

  9. Evangelista L, Cimitan M, Zattoni F, Guttilla A, Saladini G (2015) Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and[(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- to high-risk prostate cancer: a retrospective analysis. Scand J Urol 49:345–353

    Article  CAS  PubMed  Google Scholar 

  10. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N (2014) EAU guidelines on prostate cancer. part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479

    Article  CAS  PubMed  Google Scholar 

  11. Panebianco V, Sciarra A, Lisi D et al (2012) Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol 81(4):700–708

    Article  PubMed  Google Scholar 

  12. Suardi N, Gandaglia G, Gallina A et al (2015) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67(2):299–309

    Article  PubMed  Google Scholar 

  13. Ost P, Bossi A, Decaestecker K et al (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67(5):852–863

    Article  PubMed  Google Scholar 

  14. Kitajima K, Murphy RC, Nathan MA et al (2014) Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med 55(2):223–232

    Article  CAS  PubMed  Google Scholar 

  15. Castellucci P, Fuccio C, Rubello D et al (2011) Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase of 1.5 ng/ml? Eur J Nucl Med Mol Imaging 38(1):55–63

    Article  PubMed  Google Scholar 

  16. Mamede M, Ceci F, Castellucci P et al (2013) The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. Clin Nucl Med 38(9):e342–e345

    Article  PubMed  Google Scholar 

  17. Tilki D, Reich O, Graser A et al (2013) 18F-fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 63(5):792–796

    Article  PubMed  Google Scholar 

  18. Rigatti P, Suardi N, Briganti A et al (2011) Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 60(5):935–943

    Article  PubMed  Google Scholar 

  19. Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, Messa C (2012) [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 39(1):13–26. doi:10.1007/s00259-011-1920-z (Epub 2011 Sep 20)

    Article  CAS  PubMed  Google Scholar 

  20. Fuccio C, Castellucci P, Schiavina R, Guidalotti PL, Gavaruzzi G, Montini GC, Nanni C, Marzola MC, Rubello D, Fanti S (2012) Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol 81(8):e893–e896

    Article  PubMed  Google Scholar 

  21. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, Broinger G, Stoiber F, Foglman I, Langsteger W (2008) Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 35(10):1766–1774

    Article  PubMed  Google Scholar 

  22. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, Loidl W, Pirich C, Fogelman I, Langsteger W (2010) The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 12(1):98–107. doi:10.1007/s11307-009-0239-7 [(Epub 2009 Jul 9. Erratum in: Mol Imaging Biol. 2010 Jun;12(3):360)]

    Article  PubMed  Google Scholar 

  23. Ceci F, Castellucci P, Graziani T, Schiavina R, Chondrogiannis S, Bonfiglioli R, Costa S, Virgolini IJ, Rubello D, Fanti S, Colletti PM (2015) 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer. Clin Nucl Med 40(5):e265–e270

    Article  PubMed  Google Scholar 

  24. Ceci F, Herrmann K, Castellucci P et al (2014) Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging 41(12):2222–2231 [(Erratum in: Eur J Nucl Med Mol Imaging. 2014 Dec;41(12):2359)]

    Article  PubMed  Google Scholar 

  25. Soyka JD, Muster MA, Schmid DT et al (2012) Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 39(6):936–943

    Article  CAS  PubMed  Google Scholar 

  26. Goldstein J, Even-Sapir E, Ben-Haim S et al (2014) Does choline PET/CT change the management of prostate cancer patients with biochemical failure? Am J Clin Oncol [Epub ahead of print]

  27. Fanti S, Minozzi S, Castellucci P et al (2016) PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging 43(1):55–69

    Article  CAS  PubMed  Google Scholar 

  28. Karnes RJ, Murphy CR, Bergstralh EJ et al (2015) Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. J Urol 193(1):111–116

    Article  PubMed  Google Scholar 

  29. Bolla M, Van Tienhoven G, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11:1066–1073

    Article  CAS  PubMed  Google Scholar 

  30. Stephenson AJ, Bolla M, Briganti A et al (2012) Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 61(3):443–451

    Article  PubMed  Google Scholar 

  31. Wurschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M (2011) [18F] fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol 1(6):44

    Article  Google Scholar 

  32. Picchio M, Berardi G, Fodor A et al (2014) 11C-choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging 41(7):1270–1279

    CAS  PubMed  Google Scholar 

  33. Incerti E, Fodor A, Mapelli P et al (2015) Radiation treatment of lymph node recurrence from prostate cancer: is 11C-choline PET/CT predictive of survival outcomes? J Nucl Med 56(12):1836–1842

    Article  CAS  PubMed  Google Scholar 

  34. Berkovic P, De Meerleer G, Delrue L et al (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 11(1):27–32

    Article  PubMed  Google Scholar 

  35. Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S (2014) Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-choline PET/CT scan before salvage radiation therapy? J Nucl Med 55(9):1424–1429

    Article  CAS  PubMed  Google Scholar 

  36. Metzger GJ, Kalavagunta C, Spilseth B, Bolan PJ, Li X, Hutter D, Nam JW, Johnson AD, Henriksen JC, Moench L, Konety B, Warlick CA, Schmechel SC, Koopmeiners JS (2016) Detection of prostate cancer: quantitative multiparametric MR imaging models developed using registered correlative histopathology. Radiology 29:151089

    Google Scholar 

  37. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, Canini R, Grigioni W, Boschi S, Marengo M, Pettinato C, Salizzoni E, Monetti N, Franchi R, Fanti S (2005) Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46:1642–1649

    CAS  PubMed  Google Scholar 

  38. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C et al (2008) [(11)C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA leves, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 35:1065–1073

    Article  CAS  PubMed  Google Scholar 

  39. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, Bertaccini A, Manferrari F, Castellucci P, Fanti S, Canini R, Grigioni WF, D’Errico Grigioni A (2006) 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 176:954–960

    Article  CAS  PubMed  Google Scholar 

  40. Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M et al (2007) Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 244(3):797–806 (Epub 2007 Jul 24)

    Article  PubMed  Google Scholar 

  41. Bundschuh RA, Wendl CM, Weirich G et al (2013) Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging 40:824–831

    Article  PubMed  Google Scholar 

  42. Grosu AL, Weirich G, Wendl C et al (2014) 11C-choline PET/pathology image coregistration in primary localized prostate cancer. Eur J Nucl Med Mol Imaging 41:2242–2248

    Article  CAS  PubMed  Google Scholar 

  43. Van den Bergh L, Koole M, Isebaert S et al (2012) Is there an additional value of (11)C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? Int J Radiat Oncol Biol Phys 83:1486–1492

    Article  PubMed  Google Scholar 

  44. Ceci F, Castellucci P, Graziani T et al (2016) 11C-choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging 43(1):84–91

    Article  CAS  PubMed  Google Scholar 

  45. De Giorgi U, Caroli P, Burgio SL et al (2014) Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget 5(23):12448–12458

    Article  PubMed  PubMed Central  Google Scholar 

  46. Maines F, Caffo O, Donner D et al (2016) Serial (18)F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. Future Oncol 12(3):333–342

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of Nuclear Medicine, UO Medicina Nucleare PAD. 30, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Via Massarenti, 9, 40138, Bologna, Italy

    Paolo Castellucci, Francesco Ceci, Tiziano Graziani & Stefano Fanti

Authors
  1. Paolo Castellucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Ceci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tiziano Graziani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefano Fanti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Castellucci.

Ethics declarations

Funding

This study was not funded.

Conflict of interest

Paolo Castellucci, Francesco Ceci, Tiziano Graziani and Stefano Fanti declare that they do not have any conflict of interest.

Retrospective studies

For this type of study, formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castellucci, P., Ceci, F., Graziani, T. et al. PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications. Clin Transl Imaging 4, 449–456 (2016). https://doi.org/10.1007/s40336-016-0191-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40336-016-0191-x

Keywords

Search

Navigation